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Introduction: Predictors of readmission for acute exacerbations of chronic obstructive
pulmonary disease (AECOPD) are not well deﬁned. Identifying modiﬁable predictors may
help reduce the burden of readmissions. This study was done to evaluate the role of serum
magnesium in frequent readmissions.
Methods: One hundred patients admitted with a diagnosis of AECOPD to a tertiary care
center from April 2004 to March 2006 were retrospectively followed from the time of index
admission until the next admission or death. Number of admissions was calculated for the
year after index admission, and frequent readmission was deﬁned asX3 per year. Patients
with other respiratory diseases, renal failure, and congestive heart failure were excluded.
Serum magnesium was assayed at the time of admission by the colorimetric method.
Logistic regression analysis was used to ﬁnd independent risk factors for readmission.
Results: The mean age of patients was 71.9 (710.9 standard deviation (SD)) years. Fifty-
seven were females. Ninety percent were current or ex-smokers. The median duration of
time to next admission was 108 days (range 2–842). A total of 87 patients were readmitted
at least once during the ﬁrst year of follow-up, while 5% died; 23% had frequent
readmissions; 85% had received pneumococcal vaccine within 5 years; and 29% received
inﬂuenza vaccine in the current season. Frequency of readmissions was not inﬂuenced by
the administration of inhaled or oral steroids, and diuretics at the time of discharge.
Vaccination did not protect against frequent readmissions. The sole predictor of frequent
readmissions was serum magnesium level (1.7770.19 vs. 1.8670.24mEq/L; adjusted odds
ratio 0.003, 95% Conﬁdence intervals o0.001–0.55; p ¼ 0.03).Elsevier Ltd. All rights reserved.
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S.P. Bhatt et al.1000Conclusions: Lower serum magnesium level independently predicts readmission for
AECOPD. This is an easily modiﬁable risk factor.
& 2008 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is a leading
cause of morbidity and mortality and is therefore a major
public health concern. Prevalence of COPD worldwide
ranges from 4% to 10%1 and it is projected to be the third
leading cause of mortality by year 2020. Hospitalization for
acute exacerbation accounts for nearly 70% of COPD-related
health expenditure.2,3 Despite this fact, few studies have
been done to determine predictors and factors associated
with readmission. Previous studies have shown age,4 forced
expiratory volume in the 1 s (FEV1),
5–7 disease duration,6
social and psychological variables,6,8 poor performance
status5 and quality of life,8,9 history of past admissions7,8
and hypercapnea at discharge8 to be associated with
readmissions. The results have been inconsistent with
regard to certain objective markers like FEV1. Most of these
factors are reﬂectors of severe disease and poor functional
status and are not modiﬁable. In contrast, identifying
modiﬁable predictors may help reduce the burden of
readmissions.
The role of magnesium in acute exacerbations of COPD is
unclear. Lower serum magnesium levels are seen in patients
with acute exacerbations compared to stable COPD
patients.10 One indication that magnesium plays a role in
respiratory decompensation lies in studies showing low
serum magnesium in patients with severe respiratory
disorders.11 In the current study, we hypothesized that
basal serum magnesium must have some role in airway
homeostasis and that a dysregulation results in decompen-
sation. We sought to assess this hypothesis by testing
whether serum magnesium is low in acute exacerbations
and whether a low serum magnesium level affects frequent
readmissions.Methods
All patients with principal discharge diagnosis of acute
exacerbation of COPD (International Classiﬁcation of Dis-
eases 9 Code 421.21) who had been hospitalized between
April 2004 and March 2006 at a tertiary care center in
Pennsylvania were screened manually by retrieving records.
Those with secondary diagnoses of congestive heart failure,
chronic renal failure, chronic respiratory conditions other
than COPD, carcinoma lung and those with evidence of
pneumonia on chest radiograph were excluded. Patients
who did not have an at-admission serum magnesium level
were excluded. For each patient, the earliest admission
during this time period was considered index admission. The
patient was then retrospectively followed for a period of
1 year or until the next admission (whichever was longer).
Admissions during this period for reasons other than acute
exacerbations of COPD (AECOPD) were not included in the
analysis.Detailed clinical and demographic data was recorded.
This included patients’ age; smoking status and number of
pack-years; presence of co-morbidities such as diabetes
mellitus, hypertension, depression, cerebrovascular disease
ischemic heart disease; immunization with inﬂuenza and
pneumococcal vaccines; record of medications prior to
admission and at the time of discharge including broncho-
dilators, inhaled and oral steroids, statins, antacids and
proton pump inhibitors, antibiotics, diuretics, and long-term
oxygen therapy; and current pulmonary function test (PFT)
results (those within 2 years of admission) where available.
Active smokers were deﬁned as those who had been smoking
within the last 6 months. Serum magnesium was assayed at
the time of admission by bichromatic photometry using
modiﬁed methylthymol blue at 600 and 510 nm. Hypomag-
nesemia was deﬁned as serum magnesium p1.5mEq/L.
Frequent readmission was deﬁned as X3 admissions for
AECOPD in 1 year. Being a retrospective study, consent from
the internal review board was not required. A total of 1400
admissions were screened from April 2004 to March 2006 and
100 patients satisfying inclusion criteria were included in
the study.
Statistical analyses
The outcomes of interest were time to readmission and
frequent readmission. The clinical, demographic, diagnostic
and treatment variables were compared for patients with
and without frequent readmissions. The Pearson’s w2 and the
Fisher’s exact tests were used for nominal variables, and the
independent samples t-test was used for continuous vari-
ables. Multivariate logistic regression was conducted to
determine independent predictors of readmission using
variables signiﬁcant at pp0.10 based on univariate analysis.
Based on previous studies, we also included age4 and the
presence of depression6,8 in the multivariate model.
Adjusted odds ratios (ORs) were calculated, with signiﬁ-
cance at pp0.05. Finally, Cox proportional hazards regres-
sion was used to calculate the effect of serum magnesium on
time to readmission, with statistical signiﬁcance at pp0.05.
All analyses were done using SPSS version 11.5 (SPSS Inc.,
Chicago, IL).
Results
Demographic and clinical variables at initial admission are
presented in Table 1. Three patients died during the period
of follow-up. Ninety were active- or ex-smokers, 25% were
readmitted within 1 month of index admission, 43% within 3
months, 63% within 6 months and 87% within the ﬁrst year.
After index admission 44% were readmitted once in a year,
21% twice and 23% had frequent readmissions (X3/year).
Table 2 shows results of univariate and multivariate
logistic regression analyses comparing patients with
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Table 1 Demographic characteristics of patients ad-
mitted with AECOPD.
Variable Number (n) ¼ 100
Age (years) 71.9710.9 (range
48–90)






















Serum magnesium (mEq/L) 1.870.2
Duration of stay (median days) 14 (range 1–58)
Time to readmission (median
days)
108 (range 2–837)
All values expressed as mean7SD unless otherwise men-
tioned. FEV1 ¼ Forced expiratory volume in the 1 s.
Medications at the time of discharge from hospital unless
otherwise speciﬁed.
Serum magnesium is an independent predictor of frequent readmissions due to AECOPD 1001and without frequent readmissions. The overall logistic
regression model was statistically signiﬁcant (w2 ¼ 14.51,
p ¼ 0.043), indicating that the predictor variables in-
cluded in the model together differentiate between
subjects in a reliable manner regarding readmission fre-
quency. Of the 12 patients who had hypomagnesemia, three
had frequent readmissions. Additionally, 67 patients had a
current PFT.
Results of Cox proportional regression analysis revealed
that subjects with hypomagnesemia had a trend toward
shorter time to readmission, but this failed to reach
statistical signiﬁcance (140.77159.5 vs. 188.5+200.7 days,
p ¼ 0.36). Though the data indicate that for each one-point
increase in serum magnesium level, the probability of
readmission decreases by approximately 51% [G2(1) ¼ 2.36,
p ¼ 0.13], there was no statistically signiﬁcant effect of
serum magnesium levels on time to readmission. Figure 1
shows the relationship between serum magnesium and time
to readmission.Discussion
There have been few predictors of readmission for acute
exacerbation of COPD, and there have been no consistent
indicators of readmission. The factors deemed important in
previous studies have mostly been reﬂectors of poor
functional status, and in some cases like age, not modiﬁ-
able. More objective parameters like FEV1% and hypercap-
nea have been inconsistent in their ability to predict
readmission. Only one previous study looked at factors
associated with frequent readmissions, a possibly different
subset of patients.6
Two important ﬁndings were observed in our study. First,
hypomagnesemia was seen in 12% of subjects. Second, we
found that serum magnesium is an independent predictor of
frequent readmissions.
Magnesium is the second most abundant cation in the
intracellular ﬂuid and plays an important role in muscular
excitability and regulation of tone.12 The exact role of
magnesium in respiratory homeostasis is not clear. Hypo-
magnesemia is associated with increased airway hyperreac-
tivity and decreased muscle strength.13,14 It also plays a role
in airway smooth muscle relaxation and bronchodilation,
stabilization of mast cells, neurohumoral mediator release,
various immune responses, muscarinic actions and mucocili-
ary clearance.15–18 A rise in extracellular magnesium has
been shown to inhibit contractile tension of smooth
muscles.12 An indicator that magnesium has a role in
respiratory decompensation lies in studies showing low
serum magnesium in patients with severe respiratory
disorders.11 Studies in asthma have shown similar results.18
The cause of lower serum magnesium remains unclear.
While therapies for COPD such as beta agonists, steroids,
and diuretics can all theoretically lower serum magnesium
levels studies have shown conﬂicting results. A study on
effects of long-term systemic steroids showed no impact on
serum magnesium level.19 Regular inhaled steroids and beta
agonists in bronchial asthma also did not have a signiﬁcant
magnesium-lowering effect. Cohen et al.20 showed that
diuretics did not signiﬁcantly lower serum magnesium
levels. This lack of association was also seen in our study,
thereby negating a signiﬁcant therapy effect on the low
serum magnesium levels. Other studies have, however,
shown that these drugs do lower serum magnesium levels.21
In addition, our study revealed a trend toward negative
relationship between serum magnesium levels and time to
readmission. Though the difference between subjects with
hypomagnesemia and normomagnesemia showed a similar
trend, it did not reach statistical signiﬁcance. This was likely
due to low absolute numbers with hypomagnesemia. None of
the other factors independently predicted frequent read-
missions. On univariate analysis, vaccinations with inﬂuenza
and pneumococcal vaccines were associated with more
frequent readmissions at pp0.10. Vaccination with injec-
tible pneumococcal vaccine has not been conclusively shown
to be beneﬁcial in preventing hospitalizations,22 though
vaccination for inﬂuenza appears to be protective.23 This
ﬁnding has often not been seen in COPD readmission
studies,6 likely due to the fact that hospitalized patients
are more ill, as are those who get readmitted frequently.
These patients tend to get vaccinated more often than more
stable patients, leading to potential bias in outcomes.
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Age (years) 71.3710.4 72.1711.1 0.77 0.97 (0.88–1.07)
Male sex (%) 13 (57) 30 (39) 0.14 –
Current-or ex-smokers (%) 19 (83) 71 (92) 0.18 –
FEV1%* 56.673.9 45.972.8 0.08 1.003 (0.95–1.05)
Oral steroids (%) 18 (78) 69 (90) 0.16 –
Inhaled steroids (%) 10 (43) 41 (53) 0.41 –
Home oxygen therapy (%) 6 (26) 25 (32) 0.56 –
Depression (%) 10 (43) 21 (27) 0.14 2.81 (0.44–18.14)
Statin (%) 10 (43) 21 (27) 0.14 –
Pneumococcal vaccine (%)* 21 (91) 54 (70) 0.04 3.55 (0.29–43.6)
Inﬂuenza vaccine (%)* 11 (48) 18 (23) 0.02 8.22 (0.95–70.9)
BNP* 81.8720.3 130.7716.4 0.07 0.99 (0.98–1.001)
Serum magnesium (mEq/L)* 1.7770.19 1.8670.24 0.09 0.003 (0.00–0.55)y
Diuretics (%) 8 (35) 27 (35) 0.98 –
Duration of hospital stay in
index admission (days)
5.273.7 5.672.8 0.62 –
Time to readmission (days) 110.8736.0 204.3722.6 0.03 –
CI ¼ conﬁdence intervals. FEV1% ¼ percent forced expiratory volume in 1 s. *po0.1 signiﬁcant on univariate analysis. ypo0.05
signiﬁcant on multivariate logistic regression. R2 ¼ 0.42.
Figure 1 Relationship between serum magnesium and time to
readmission.
S.P. Bhatt et al.1002Our study had some limitations. Being a retrospective
study, we could include only those patients who had serum
magnesium measured at the time of admission. However,
since magnesium was measured as part of an electrolytepanel irrespective of disease severity, we believe this did
not cause a selection bias. We could not assess serum
magnesium levels during stable phases in these patients to
see if the low serum magnesium played a role of patho-
physiology of the acute exacerbations. Not all patients had a
PFT but the number of patients with a PFT was comparable
to other retrospective studies.24 However, we did include
most of the potentially important parameters included in
previous studies.
In conclusion, we determined that serum magnesium is an
independent predictor of frequent readmissions for acute
exacerbations of COPD. This is a modiﬁable risk factor and
we recommend that serum magnesium be determined in all
patients admitted for AECOPD. Further studies involving
magnesium supplementation are needed to determine if this
can indeed alter the course of the disease in a selected
cohort.Conﬂict of Interest statement
All authors declare that we have no actual or potential
ﬁnancial interest or any conﬂict of interest.References
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